PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic Journal

European Psychologist

1 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

European Psychologist has 1 tracked paper indexed in Blossom (2022) from 2 authors, most often covering LSD, DMT and Psilocybin, across Major Depressive Disorder (MDD), Depressive Disorders and Anxiety Disorders.

Published Papers

Paywallmeta

New insights into the clinical and nonclinical effects of psychedelic substances: An integrative review.

This review (2022) explores the potential of psychedelics in treating mental health disorders, their short- and long-term effects on recreational users, and the neurological and cognitive processes responsible for their effects using the most up to date research. The positive findings of psilocybin for depression (MDD) and anxiety are highlighted. The mystical experience (MEQ) also plays a large role, but individual differences (for whom does it work) are still not well examined.

Published
May 23, 2022
Journal
European Psychologist
Authors
Forstmann, M., Sagioglou, C.

Quick Facts

Papers Indexed
1
h-Index
77
Open Access
No
Publisher
Hogrefe Publishing
Country
United States
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.